Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 99 peer-reviewed journal articles Updated
Cardiology · Wild-Type ATTR Amyloidosis

Understanding Wild-Type ATTR Amyloidosis

At a Glance

Wild-type ATTR amyloidosis (wtATTR) is a non-hereditary, age-related condition where normal proteins misfold and build up in the heart, causing stiffness and heart failure. While often misdiagnosed initially, new stabilizer medications can stop the disease from worsening if caught early.

If you have been told you have wild-type transthyretin amyloidosis (wtATTR), you may feel a mix of relief at finally having an answer and concern about what it means for your future. This condition occurs when a normal protein in your body becomes unstable and begins to form clumps that interfere with your heart’s ability to function [1][2].

Understanding the biological “why” behind your symptoms can help you take control of your care. While the journey to this diagnosis is often long and frustrating, modern medicine has made significant strides in identifying and treating this condition [3][4].

What is wtATTR?

The “wt” in wtATTR stands for wild-type, which is a scientific term meaning “normal” or “not mutated.” In your body, a protein called transthyretin (TTR) is produced by the liver. Its normal job is to transport Vitamin A and thyroid hormone through your bloodstream [5][6].

Usually, the TTR protein is shaped like a stable four-leaf clover (a tetramer). However, as a natural part of aging for some people, this clover shape can become unstable and fall apart into individual “leaves” called monomers [7][5]. These loose monomers misfold and stick together to create long, tough fibers called amyloid fibrils. These fibrils deposit in the tissues of the heart, causing the heart walls to become thick and stiff—a condition known as amyloid cardiomyopathy (ATTR-CM) [1][8].

Is it Hereditary?

One of the most important things to know is that wild-type ATTR is not an inherited genetic disease [9].

  • Wild-Type (wtATTR): Caused by age-related protein instability. It is not passed down to children or grandchildren [5][10].
  • Hereditary (hATTR): Caused by a specific mutation in the TTR gene that someone is born with. This form can be passed through families [5][11]. A simple genetic test is required to confirm which type you have.

Why the Diagnosis Often Takes Time

It is very common for wtATTR to be missed or misdiagnosed for years [4][12]. This is not usually due to poor care, but rather because wtATTR “mimics” more common conditions.

The HFpEF “Mask”

Many patients are initially told they have HFpEF (Heart Failure with Preserved Ejection Fraction). This is a broad term for heart failure where the heart still pumps blood out well, but the chambers are too stiff to fill properly [1][2]. Because wtATTR makes the heart walls thick and stiff, its “hemodynamic profile” (the way blood moves through the heart) looks exactly like other forms of HFpEF [13][14].

The “Red Flag” Clues

Research shows that wtATTR often leaves clues in other parts of the body years before heart symptoms appear. These are called extracardiac manifestations [15]. You may have experienced:

  • Bilateral Carpal Tunnel Syndrome: Numbness or tingling in both hands, often occurring 5 to 15 years before heart symptoms [15][16].
  • Spinal Stenosis: Narrowing of the spinal canal in the lower back [17].
  • Biceps Tendon Rupture: Often called a “Popeye deformity” in the upper arm [15].

Validating Your Journey

The path to a wtATTR diagnosis can be emotionally exhausting. Studies show that the long search for answers—often involving multiple specialists and years of uncertainty—frequently leads to significant psychosocial distress, including anxiety and a sense of being overwhelmed [18][19].

If you felt that your symptoms weren’t being fully explained by “normal aging” or “high blood pressure,” your intuition was right. The medical community now recognizes that the delayed recognition of this disease is a major challenge that needs to be addressed through better screening and awareness [18][20].

A Turning Point in Care

The most encouraging news is that the understanding of wtATTR has changed dramatically. We now have:

  1. Non-Invasive Testing: Specialized scans (like the PYP scan) often allow for a diagnosis without needing a heart biopsy [21][22].
  2. Stabilizer Therapies: Medications like tafamidis act like “molecular glue.” They bind to the TTR protein to keep it in its stable clover shape, preventing it from falling apart and forming more amyloid [23][24]. It is important to know that these medications are designed to stabilize the disease and prevent it from getting worse, rather than reversing the damage that has already occurred.

Starting these treatments early is key to protecting your heart function and improving your quality of life [3][25].

For a deeper understanding of your condition and what comes next, please navigate to the following sections:

01

Connecting the Dots: Symptoms and Warning Signs

Learn the warning signs of wild-type ATTR amyloidosis (wtATTR). Understand the timeline from early orthopedic issues like carpal tunnel to heart symptoms.

02

Getting the Right Answer: Diagnosis and Avoiding Misdiagnosis

Learn the correct testing pathway for wild-type ATTR amyloidosis (wtATTR). Understand bone scans, why you must rule out AL, and the need for genetic testing.

03

Understanding Your Stage and Outlook

Learn how doctors stage wild-type ATTR (wtATTR) amyloidosis using the NAC and Mayo systems. Understand NT-proBNP, eGFR, and how your stage guides treatment.

04

Managing wtATTR: Standard of Care and New Directions

Learn about wild-type ATTR amyloidosis (wtATTR) treatments. Understand TTR stabilizers like tafamidis, new therapies, and which heart medications to avoid.

05

Daily Life and Long-Term Monitoring

Learn how to manage daily life with wild-type ATTR amyloidosis (wtATTR). Understand fluid balance, daily weigh-ins, symptom monitoring, and scan schedules.

Common questions in this guide

Is wild-type ATTR amyloidosis hereditary?
No, wild-type ATTR amyloidosis is not an inherited condition and cannot be passed down to your children. It is caused by age-related changes to normal proteins in your body, rather than a genetic mutation.
Why is wtATTR often misdiagnosed at first?
The condition makes the heart walls thick and stiff, which closely mimics a common type of heart failure called HFpEF. Because the symptoms look identical to more common heart issues, it can take years to get the correct diagnosis.
How does carpal tunnel syndrome relate to a heart diagnosis?
Before affecting the heart, misfolded amyloid proteins can build up in the ligaments of your wrists. Developing carpal tunnel syndrome in both hands is a common early warning sign that can occur five to fifteen years before heart symptoms appear.
What treatments are available for wild-type ATTR amyloidosis?
Treatment primarily involves TTR-stabilizer medications like tafamidis. These drugs act as molecular glue to keep the proteins stable, preventing them from forming more amyloid deposits and protecting your remaining heart function.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific findings on my heart imaging or scans point toward wtATTR?
  2. 2.Was monoclonal gammopathy (AL amyloidosis) ruled out using both blood and urine tests?
  3. 3.Has my genetic testing been ordered to confirm this is definitely the 'wild-type' form?
  4. 4.How does my history of carpal tunnel syndrome or spinal stenosis relate to this heart diagnosis?
  5. 5.Now that we have a diagnosis, what are the next steps for starting a TTR-stabilizing therapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Cardiac amyloidosis: An underdiagnosed/underappreciated disease.

    Manolis AS, Manolis AA, Manolis TA, Melita H

    European journal of internal medicine 2019; (67()):1-13 doi:10.1016/j.ejim.2019.07.022.

    PMID: 31375251
  2. 2

    Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis.

    Eldhagen P, Berg S, Lund LH, et al.

    Journal of internal medicine 2021; (289(6)):895-905 doi:10.1111/joim.13222.

    PMID: 33274477
  3. 3

    Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.

    Capovilla TM, Lalario A, Rossi M, et al.

    Heart failure clinics 2024; (20(3)):333-341 doi:10.1016/j.hfc.2024.03.007.

    PMID: 38844304
  4. 4

    Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS.

    Mora-Ayestaran N, Dispenzieri A, Kristen AV, et al.

    JACC. Advances 2024; (3(8)):101086 doi:10.1016/j.jacadv.2024.101086.

    PMID: 39105117
  5. 5

    Transthyretin: Its function and amyloid formation.

    Ueda M

    Neurochemistry international 2022; (155()):105313 doi:10.1016/j.neuint.2022.105313.

    PMID: 35218869
  6. 6

    In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin Proteolysis.

    Bezerra F, Niemietz C, Schmidt HHJ, et al.

    International journal of molecular sciences 2021; (22(17)) doi:10.3390/ijms22179488.

    PMID: 34502397
  7. 7

    Glavonoid, a possible supplement for prevention of ATTR amyloidosis.

    Matsushita H, Isoguchi A, Okada M, et al.

    Heliyon 2021; (7(10)):e08101 doi:10.1016/j.heliyon.2021.e08101.

    PMID: 34693047
  8. 8

    Advantages and Emerging Problems of Novel Treatments for Transthyretin Cardiac Amyloidosis.

    Okumura T, Murohara T

    Circulation journal : official journal of the Japanese Circulation Society 2019; (84(1)):9-10 doi:10.1253/circj.CJ-19-1044.

    PMID: 31813898
  9. 9

    Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future.

    Obici L, Mussinelli R

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; (18(4)):2286-2302 doi:10.1007/s13311-021-01154-y.

    PMID: 34850359
  10. 10

    From Molecular to Radionuclide and Pharmacological Aspects in Transthyretin Cardiac Amyloidosis.

    Stanciu SM, Jurcut R, Dragoi Galrinho R, et al.

    International journal of molecular sciences 2024; (26(1)) doi:10.3390/ijms26010146.

    PMID: 39796004
  11. 11

    Hereditary transthyretin-related amyloidosis.

    Finsterer J, Iglseder S, Wanschitz J, et al.

    Acta neurologica Scandinavica 2019; (139(2)):92-105 doi:10.1111/ane.13035.

    PMID: 30295933
  12. 12

    Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy.

    Witteles RM, Chung H, Dai F, et al.

    Frontiers in cardiovascular medicine 2025; (12()):1638380 doi:10.3389/fcvm.2025.1638380.

    PMID: 41235331
  13. 13

    The impact of large v-waves of pulmonary artery wedge pressure in patients with wild-type transthyretin amyloid cardiomyopathy.

    Yamamoto M, Izumiya Y, Takashio S, et al.

    Journal of cardiology 2026; (87(3)):221-229 doi:10.1016/j.jjcc.2025.11.008.

    PMID: 41319728
  14. 14

    A simple ATTR-CM score to identify transthyretin amyloid cardiomyopathy burden in HFpEF patients.

    Ye M, Liu X, Gu Z, et al.

    European journal of clinical investigation 2023; (53(11)):e14045 doi:10.1111/eci.14045.

    PMID: 37357789
  15. 15

    Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS).

    Ladefoged B, Clemmensen T, Dybro A, et al.

    ESC heart failure 2023; (10(1)):234-244 doi:10.1002/ehf2.14173.

    PMID: 36193570
  16. 16

    The Emerging Significance of Amyloid Deposits in the Ligamentum Flavum of Spinal Stenosis Patients: A Review.

    Wang AY, Patel J, Kanter M, et al.

    World neurosurgery 2023; (177()):88-97 doi:10.1016/j.wneu.2023.06.037.

    PMID: 37331471
  17. 17

    Transthyretin amyloid cardiomyopathy: Literature review and red-flag symptom clusters for each cardiology specialty.

    Izumiya Y, Kubo T, Endo J, et al.

    ESC heart failure 2025; (12(2)):955-967 doi:10.1002/ehf2.15016.

    PMID: 39168835
  18. 18

    Single German centre experience with patient journey and care-relevant needs in amyloidosis: The German AMY-NEEDS research and care program.

    Ihne-Schubert SM, Leberzammer M, Weidgans M, et al.

    PloS one 2024; (19(5)):e0297182 doi:10.1371/journal.pone.0297182.

    PMID: 38768126
  19. 19

    Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey.

    Abdallah NH, Hydren JR, Barnes MS, et al.

    Clinical lymphoma, myeloma & leukemia 2026; (26(3)):184-190 doi:10.1016/j.clml.2026.01.003.

    PMID: 41638973
  20. 20

    The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement.

    Karam C, Moffit C, Summers C, et al.

    Orphanet journal of rare diseases 2024; (19(1)):419 doi:10.1186/s13023-024-03407-3.

    PMID: 39516862
  21. 21

    Updates in Cardiac Amyloidosis Diagnosis and Treatment.

    Stern LK, Kittleson MM

    Current oncology reports 2021; (23(4)):47 doi:10.1007/s11912-021-01028-8.

    PMID: 33725199
  22. 22

    Diagnosis of Transthyretin Amyloid Cardiomyopathy.

    Hafeez AS, Bavry AA

    Cardiology and therapy 2020; (9(1)):85-95 doi:10.1007/s40119-020-00169-4.

    PMID: 32266575
  23. 23

    Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic Benefits.

    Powers ET, Amass L, Baylor L, et al.

    Cardiology and therapy 2025; (14(3)):333-350 doi:10.1007/s40119-025-00423-7.

    PMID: 40730935
  24. 24

    Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.

    Judge DP, Heitner SB, Falk RH, et al.

    Journal of the American College of Cardiology 2019; (74(3)):285-295 doi:10.1016/j.jacc.2019.03.012.

    PMID: 30885685
  25. 25

    Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

    Maurer MS, Schwartz JH, Gundapaneni B, et al.

    The New England journal of medicine 2018; (379(11)):1007-1016 doi:10.1056/NEJMoa1805689.

    PMID: 30145929

This page provides educational information about wild-type ATTR amyloidosis and its symptoms. It does not replace professional medical advice, diagnosis, or treatment from your cardiologist or amyloidosis specialist.

Get notified when new evidence is published on Wild type ATTR amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.